Growth Opportunities in the Global Molecular Diagnostics Industry
How AI, Multi-omics, and Precision Medicine Are Reshaping Molecular DiagnosticsMolecular diagnostics is becoming more central to precision medicine as demand grows for earlier disease detection, personalized treatment strategies, and data-driven clinical decisions. Innovations across sequencing technologies, liquid biopsy, and companion diagnostics are reshaping the competitive landscape. This analysis also highlights the industry developments, technologies, and partnerships shaping molecular diagnostics.
Explore the Growth Opportunities
Ecosystem Snapshot
|
Industry Size (2031)
$38.74 billion
|
Growth Rate
5.7% CAGR
|
Key Focus Areas
Companion Diagnostics, AI-enabled Genomic Workflow Systems, Blood-based Diagnostics
|
How will your organization respond as molecular diagnostics advances through platform expansion, AI-enabled workflows, and stronger diagnostics-pharma collaboration?
What You’ll Find in Frost & Sullivan’s Latest Analysis
Regulatory Momentum and Clinical Adoption
A closer look at the regulatory activity supporting advanced molecular diagnostic technologies, including next-generation sequencing (NGS)-based profiling, liquid biopsy, companion diagnostics, and blood-based biomarker tests.
Technology Convergence
How digital PCR (dPCR), NGS, CRISPR-Cas, and nanotechnology are coming together to create faster, more accurate, and more scalable molecular testing ecosystems.
Competitive Landscape
What nearly 90 molecular diagnostics companies across platform- and service-based models reveal about the shift from traditional testing toward data-driven precision medicine.